Liposomal drug delivery systems: from concept to clinical applications.

By Theresa M. Allen, P. Cullis. Advanced Drug Delivery Reviews, 2013

4,362 citations recorded by the source corpus.

Subfields: Biomaterials, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/b8bb9bdebf669c6ac9ea5b0954696f96646e07cf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. S. Hua
2. E. Holler
3. J. Ljubimova
4. J. Markman
5. A. Rekechenetskiy
6. Ning Gu
7. F. Xiong
8. Fang Yang

In Molecular Biology

1. S. Hua
2. J. Ljubimova
3. E. Holler
4. J. Markman
5. A. Rekechenetskiy
6. M. Hope
7. Sameer Quazi
8. Tomasz M. Karpinski

Citations in the corpus

• The Smart Drug Delivery System and Its Clinical Potential (2016, background): “Although recent research and reviews have developed and summarized several novel aspects for nanomaterials that being used as smart drug carriers [1-6], few of them have been finally translated into clinics for real-world applications [7-9].”
• Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “Potential reasons for this discrepancy have previously been reviewed (Sawant and Torchilin, 2012; Allen and Cullis, 2013), and include factors such as target accessibility and expression, disease-dependent anatomical and physiological barriers, and formulation stability.”
• Engineering the Delivery System for CRISPR-based Genome Editing (2018, background): “Lipid-based drug carriers have been FDA-approved for small molecule delivery since the 1980s [42].”
• Smart nanoparticles for cancer therapy (2023, background): “49 Smart liposomes that have been functionally changed are also sensitive to a variety of internal and external stimuli, such as enzyme transformations, pH changes, redox reactions, microwaves, ultrasound, and light.”
• Liposomes: structure, composition, types, and clinical applications (2022, background): “Liposomes' active targeting increases the selectivity of liposome interaction with diseased cells and triggers receptor-mediated endocytosis of the liposome and its payload into the desired cellular target [101, 102].”